On the other hand, to prevent the risk and recurrence of lymphoma associated with anti-TNFα Abs for RA patients, rituximab (anti-CD20 Ab, Mabthera) was recommended to replace anti-TNFα Abs, which can be a dual agent that inhibits the progression of lymphoma and RA disease activity [16]. This evidence concerns the gene TNF and rheumatoid arthritis.